Summary
41 patients with stable, frequent, chronic premature ventricular contractions have been treated with aprindine, and its therapeutic effectiveness evaluated by continuous electrocardiographic recording on tape. Excellent results (total suppression of the dysrhythmia) were obtained in 29 patients (71%), in whom the minimal effective plasma level ranged from 0.73 to 2.55 µg/ml (mean 1.35 µg/ml). Neurological side effects developed in 9 patients (22%), with plasma levels from 1.19 to 4.13 µg/ml (mean 2.65 µg/ml). The value of plasma level determinations is discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Atkinson, A. J.: Clinical use of blood levels of cardiac drugs. Mod. Conc. cardiov. Dis.42, 1–4 (1973)
Bloomfield, S. S., Romhilt, D. W., Te-Chuan-Chou, Flowler, N. O.: Quinidine for prophylaxis of arrhythmias in acute myocardial infarction. New Engl. J. Med.285, 979–986 (1971)
Dodion, L., De Suray, J. M., De Blecker, M., Georges, A.: Caractéristiques pharmacocinétiques et biodégradation de l'aprindine chez l'homme. Therapie (In press)
Dollery, C. T.: Pharmacokinetics — Master or Servant? Eur. J. clin. Pharmacol.6, 1–2 (1973)
Fassola, A. F.: The pharmacology and clinical evaluation of aprindine. A new antiarrhythmic agent. Acta Cardiol. (Brux.) In press
Georges, A., Hosslet, A., Duvernay, G.: Pharmacological evaluation of aprindine (AC 1802) a new antiarrhythmic agent. Acta Cardiol. (Brux.)28, 166–191 (1973)
Holter, N. J.: New method for heart studies. Science134, 1214–1220 (1961)
Kesteloot, H., Van Mieghem, W., De Geest, H.: Aprindine (AC 1802) a new antiarrhythmic drug. Acta Cardiol. (Brux.)28, 145–165 (1973)
Koch-Weser, J., Klein, S. W., Foo-Canto, L. L., Kastor, J. A., Desanctis. R. W.: Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction. New Engl. J. Med.281, 1253–1260 (1969)
Koch-Weser, J., Klein, S. W.: Procainamide dosage schedules, plasma concentrations and clinical effects. J. Amer. med. Ass.215, 1454–1460 (1971)
Lown, B., Vassaux, C.: Lidocaine in acute myocardial infarction. Amer. Heart J.76, 586–587 (1968)
Lown, B., Wolf, M.: Approaches to sudden death from coronary heart disease. Circulation44, 130–142 (1973)
Melmon, K. L., Morrelli, H. F.: Clinical Pharmacology, p. 186. New York: Macmillan 1972
Sjöqvist, F., Beryilsson, L.: Plasma concentrations of drugs and pharmacological response in man. In “Biological effects of drugs in relation to their plasma concentrations”, p. 25–40. London and Basingstoke: Macmillan 1973
Van Durme, J. P., Rosseel, M.-T., Bogaert, M. G.: Therapeutic effectiveness and plasma levels of a new antidysrhythmic drug: aprindine. Acta Cardiol. (Brux.) (In press)
Van Durme, J. P., Rousseau, M., Mbuyamba, P.: Treament of chronic ventricular dysrhythmias with a new drug: aprindine (AC 1802). Acta Cardiol. (Brux.) (In press)
Veronck, F., Vereecke, J., Vleugels, A.: Electrophysiological effects of aprindine on isolated heart preparations. Eur. J. Pharmacol.26, 338–347 (1974)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van Durme, J.P., Bogaert, M.G. & Rosseel, M.T. Therapeutic effectivenss and plasma levels of aprindine, a new antidysrhythmic drug. Eur J Clin Pharmacol 7, 343–346 (1974). https://doi.org/10.1007/BF00558203
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558203